A decision by the Department of Health and Human Services to open access to six unapproved peptides marks a significant departure from standard drug regulation, underscoring a philosophical shift toward deregulation and consumer choice over agency consensus. The draft guidance, announced Wednesday by Health and Human Services Secretary Robert F. Kennedy Jr., directs federal regulators to withhold enforcement actions against certain specialty pharmacies preparing the unproven wellness substances.
Peptides, which are chains of amino acids shorter than conventional proteins, include widely prescribed, approved medications such as insulin and GLP-1 treatments for diabetes and weight loss. However, the six substances outlined in the new directive — BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 — have not completed the rigorous clinical testing required for Food and Drug Administration clearance. There are no published clinical trials demonstrating that these specific peptides are effective in humans for any medical condition, ABC News reported.
Tension between federal leadership and agency scientists
The policy reflects deepening friction between federal health leadership and career scientific staff. According to The Guardian, FDA drug review staffers overwhelmingly resisted the initiative, arguing that relaxing restrictions threatens the agency’s primary mission of shielding consumers from unvetted pharmaceuticals. While an independent FDA advisory panel voted in July to recommend allowing the six peptides into specialized compounding, internal agency researchers testified against the change, citing insufficient evidence supporting safety or efficacy.
HHS officials initially sought a formal federal regulation to declare the substances safe for compounding, The Guardian reported. When scientific personnel pushed back, the department pivoted to an enforcement discretion model, effectively directing regulators to look the other way rather than formally approving the compounds. Federal law grants HHS ultimate authority over pharmaceutical rules, but former regulators note it is exceedingly unusual for the cabinet department to circumvent standard FDA rulemaking on compounded drugs.
The gray market dilemma
Supporters of the directive argue that bringing the compounds into licensed pharmacies creates an essential harm-reduction mechanism. In recent years, an illicit market has flourished, with consumers purchasing vials labeled for laboratory research from online vendors and foreign chemical makers. Recent reporting by CBS News illustrated the hazards of this gray market when a sample of an unapproved weight-loss substance bought at a New York bodega tested entirely negative for the advertised peptide.
Under the new draft rules, compounders must secure active ingredients from FDA-registered facilities, obtain laboratory certificates, require patient-specific prescriptions and log adverse reactions. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, told NPR that the policy creates a more accountable environment backed by regulatory standards and safety reporting.
Public health risks and supply constraints
Consumer advocates and health watchdogs contend the shift sets a dangerous precedent by sidestepping scientific validation. Dr. Robert Steinbrook, director of Public Citizen’s Health Research Group, said in a statement reported by NPR that bypassing standard evaluation processes undermines the FDA and threatens the public by allowing unproven compounds to reach patients without federal enforcement.
Questions also linger regarding whether pharmacies can meet consumer demand. The policy restricts compounding to small, state-licensed 503A pharmacies and excludes larger 503B outsourcing facilities, NPR reported. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals, told NPR that small compounders will likely struggle to satisfy public interest, noting his firm may only be able to produce one of the six substances in modest amounts.
The draft policy opens for public comment on Friday and will accept feedback through Nov. 13. The measure is intended to remain in effect until the FDA crafts a formal rule, though the agency has not yet proposed one.
